Biocon Limited (NSE:BIOCON)
India · Delayed Price · Currency is INR 395.25
-1.60 (-0.40%)
Nov 24, 2025, 3:30 PM IST
Biocon Revenue
Biocon had revenue of 42.96B INR in the quarter ending September 30, 2025, with 19.64% growth. This brings the company's revenue in the last twelve months to 164.76B, up 10.62% year-over-year. In the fiscal year ending March 31, 2025, Biocon had annual revenue of 152.62B with 3.43% growth.
Revenue (ttm)
164.76B
Revenue Growth
+10.62%
P/S Ratio
3.20
Revenue / Employee
10.10M
Employees
16,315
Market Cap
527.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 152.62B | 5.06B | 3.43% |
| Mar 31, 2024 | 147.56B | 35.82B | 32.05% |
| Mar 31, 2023 | 111.74B | 29.90B | 36.54% |
| Mar 31, 2022 | 81.84B | 10.41B | 14.57% |
| Mar 31, 2021 | 71.43B | 8.43B | 13.37% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Aurobindo Pharma | 325.14B |
| Cipla | 279.66B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Glenmark Pharmaceuticals | 159.97B |
| Alkem Laboratories | 138.90B |
| Mankind Pharma | 135.46B |
Biocon News
- 4 days ago - Biocon shares fall sharply over 3% as Citi downgrades stock to ‘Sell’ with target price to Rs 360 - Business Upturn
- 5 days ago - Biocon subsidiary gets U.S. FDA approval for Tofacitinib Extended-Release tablets - Business Upturn
- 10 days ago - Biocon clarifies on merger speculation, says committee still evaluating restructuring options - Business Upturn
- 11 days ago - US Proposal Could Halve Biocon's Biosimilar Development Costs - NDTV
- 11 days ago - Biocon shares surge over 3% today on strong Q2 performance: Should you buy the stock? — explained - Business Upturn
- 11 days ago - Biocon MD says board has not taken any action on Biocon Biologics merger yet: Report - Business Upturn
- 11 days ago - Stocks to buy today, Nov 13: Honasa, HAL, Tata Steel, Biocon, UPL, Asian Paints, and more among top brokerage recommendations - Business Upturn
- 12 days ago - Biocon Ltd (BOM:532523) (HY 2026) Earnings Call Highlights: Strong Growth in Biosimilars and ... - GuruFocus